BioNTech (NASDAQ:BNTX) Price Target Lowered to $128.00 at BMO Capital Markets

BioNTech (NASDAQ:BNTX) had its price target decreased by BMO Capital Markets from $143.00 to $128.00 in a research note published on Wednesday morning, Marketbeat.com reports. BMO Capital Markets currently has an outperform rating on the stock.

A number of other equities research analysts have also recently weighed in on the company. Berenberg Bank reiterated a “buy” rating on shares of BioNTech in a research note on Friday, January 23rd. UBS Group upgraded shares of BioNTech to a “hold” rating in a research report on Thursday, December 4th. Raymond James Financial reiterated an “outperform” rating on shares of BioNTech in a research report on Tuesday. Bank of America reiterated a “buy” rating and set a $128.00 price target on shares of BioNTech in a research note on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research note on Friday, January 9th. Twelve investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and an average target price of $133.73.

BioNTech Stock Up 8.3%

BioNTech stock opened at $90.84 on Wednesday. The company has a market capitalization of $20.46 billion, a P/E ratio of -17.34 and a beta of 1.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.12. BioNTech has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The stock has a 50-day simple moving average of $106.64 and a 200-day simple moving average of $102.75.

Institutional Investors Weigh In On BioNTech

Several hedge funds have recently modified their holdings of BNTX. Larson Financial Group LLC increased its stake in BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after buying an additional 127 shares during the period. EFG International AG acquired a new stake in shares of BioNTech in the 4th quarter worth $29,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of BioNTech by 520.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after acquiring an additional 260 shares in the last quarter. Financial Consulate Inc. acquired a new position in shares of BioNTech during the third quarter worth about $36,000. Finally, Huntington National Bank raised its holdings in BioNTech by 1,266.7% during the third quarter. Huntington National Bank now owns 410 shares of the company’s stock worth $40,000 after purchasing an additional 380 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting BioNTech

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Q4 results beat consensus on both EPS and revenue (EPS -$0.39 vs -$0.57 expected; revenue ~$1.06B vs $942M expected); management highlighted a strong cash position and multiple upcoming late‑stage readouts. Earnings Press Release
• Positive Sentiment: Analysts remain generally constructive: Canaccord reaffirmed a Buy with a $171 PT and Goldman Sachs also reaffirmed Buy — these positive analyst stances can support near‑term buying interest. Canaccord Note
• Neutral Sentiment: BioNTech announced plans to contribute certain rights/technologies to a new independent company led by co‑founders; BioNTech will retain a minority stake and may receive milestones/royalties — could free focus/resources but adds execution complexity. Company Release
• Neutral Sentiment: Reported short‑interest data in March shows zero shares (likely a reporting/data anomaly) — not meaningful for sentiment at this time.
• Negative Sentiment: Co‑founders Prof. Ugur Sahin and Prof. Özlem Türeci plan to leave by end of 2026 to launch a new mRNA company — markets view founder exits as a governance and execution risk, which triggered heavy selling. Reuters
• Negative Sentiment: FY‑2026 revenue guidance was lowered materially (company now sees ~€2.0–2.3B vs consensus nearer €3.1B) — the weaker outlook is a primary driver of the recent selloff. Full Results & Guidance
• Negative Sentiment: Multiple outlets reported a steep one‑day stock drop after the earnings/guidance and founder news; several brokers have cut price targets (Jefferies, Citigroup, BMO lowered PTs; TD Cowen moved to Hold) — analyst downgrades/PT cuts amplify downside pressure. Analyst Notes Summary
• Negative Sentiment: Investor litigation/claims firm Johnson Fistel announced an inquiry into potential shareholder claims related to executive actions — adds legal/ reputational overhang. Johnson Fistel Notice

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.